Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
96.46
+1.17 (1.23%)
Oct 20, 2026, 10:32 AM EDT - Market open
Insmed Revenue
Insmed had revenue of $425.49M in the quarter ending June 30, 2026, with 296.11% growth. This brings the company's total for the last twelve months to $1.14B, up 185.76% year-over-year. In the year 2025, Insmed had annual revenue of $606.42M with 66.73% growth. That makes Insmed the 7,047th largest company in the world by revenue and 1,711th in the United States.
Revenue (ttm)
$1.14B
Revenue Growth
+185.76%
P/S Ratio
18.29
Revenue / Employee
$683,675
Employees
1,664
Market Cap
21.07B
Revenue by Segment
- ARIKAYCE 433.77M 71.5%
- BRINSUPRI 172.66M 28.5%
Fiscal year ended Dec 31, 2025 See the full Insmed breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 606.42M | 242.72M | 66.73% |
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | 136.47M | 126.63M | 1,287.56% |
| Dec 31, 2018 | 9.84M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 11.50M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 4.42M | -2.50M | -36.18% |
| Dec 31, 2010 | 6.92M | -3.45M | -33.28% |
| Dec 31, 2009 | 10.37M | -1.33M | -11.33% |
| Dec 31, 2008 | 11.70M | 4.12M | 54.32% |
| Dec 31, 2007 | 7.58M | 6.56M | 639.61% |
| Dec 31, 2006 | 1.03M | 894.00K | 682.44% |
| Dec 31, 2005 | 131.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
INSM News
- 1 hour ago - Insmed price target lowered to $173 from $187 at Raymond James - TheFly
- 3 hours ago - Insmed Appoints Two New Directors to Its Board - PRNewsWire
- 1 day ago - Insmed announces commercial launch of brinsupri tablets in Japan - TheFly
- 1 day ago - Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan - PRNewsWire
- 4 days ago - Roth Capital healthcare analysts hold analyst/industry conference call - TheFly
- 5 days ago - Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 - PRNewsWire
- 6 days ago - Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 - PRNewsWire
- 8 days ago - Insmed price target lowered to $207 from $214 at BofA - TheFly